Patients with anti-SRP antibodies have a clinical pattern typical of PM (typically developing rapidly progressive, severe, proximal muscle weakness with frequent occurrence of muscle atrophy) [2] [3] [4] . In general, patients have extremely high CK levels at presentation. The histological appearance of muscle biopsy specimens in anti-SRP myopathy is of sparse inflammatory infiltrate but significant muscle necrosis [2, 4] .
In general, patients with anti-SRP antibodies have a good initial response to high-dose steroid therapy but the myopathy relapses with dose reduction leading to the requirement for very high cumulative doses of steroids [4] . Both of our patients failed AZA, MTX and mycophenolate mofetil prior to B-cell depletion therapy as is typical in these patients [3] .
Anti-SRP myopathy is felt to be the disease primarily of the humoral immune system [5] and anti-SRP antibodies have been shown to inhibit the function of signal recognition proteins by inhibiting the binding of SRP to the SRP receptor [6] , supporting a role for B-cell depletion in the treatment of the disease.
Rituximab has been used on a number of occasions for the treatment of refractory myositis [7] [8] [9] and good results have been reported in the treatment of anti-SRP myopathy with the use of rituximab following plasma exchange [5] . In our experience, whereas both patients had a rapid biochemical response the clinical response was not as impressive as previously reported. This may be due to the fact that some SRP-positive patients have been noted to have a paucity of hypertrophic fibres on muscle biopsy suggesting that the persistent weakness may be due to a lack of compensatory muscle hypertrophy [3] .
In summary, we have reported our experience of treating two patients with anti-SRP myopathy, with aggressive B-cell depletion. Both patients had a poor clinical response, which is in contrast to the only other report of the use of rituximab in this patient population. 
